Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive

Highlights • Challenges of rapid COVID-19 drug development risk to compromise good scientific practice• Access to patient-level data especially urgent to address risks of protocol violations and rapid reviews.• Open access to data enables transparency, secondary analyses, and meta-analyses.• Politicization of scientific reports will be reduced by cross-checking and multilateral analyses.

[1]  Kristin L. Sainani,et al.  Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials , 2017, JAMA internal medicine.

[2]  Fiona Godlee,et al.  Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors , 2017, Journal of Korean medical science.

[3]  Harlan M Krumholz,et al.  Open Access Platforms for Sharing Clinical Trial Data. , 2016, JAMA.

[4]  H. Bauchner,et al.  Sharing Clinical Trial Data: A Proposal from the International Committee of Medical Journal Editors , 2016, PLoS medicine.

[5]  Sean M. O'Brien,et al.  Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials , 2020, medRxiv.

[6]  Catrin Tudur Smith,et al.  UK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concerns , 2016, Journal of clinical epidemiology.

[7]  The Editors of the Lancet Group.  Learning from a retraction , 2020, The Lancet.

[8]  E. Akl,et al.  A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis , 2020, Journal of Clinical Epidemiology.

[9]  Howard Bauchner,et al.  Randomized Clinical Trials and COVID-19: Managing Expectations. , 2020, JAMA.

[10]  Neal R Haddaway,et al.  Open synthesis and the coronavirus pandemic in 2020 , 2020, Journal of Clinical Epidemiology.

[11]  J. Ioannidis,et al.  Evaluation of Clinical Trial Data Sharing Policy in Leading Medical Journals , 2020, medRxiv.

[12]  J. Ioannidis,et al.  Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters , 2020, Environmental Research.

[13]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[14]  J. Yazdany,et al.  Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know , 2020, Annals of Internal Medicine.

[15]  G. Koh,et al.  Faculty Opinions recommendation of Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. , 2020 .

[16]  Amit N. Patel,et al.  Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. , 2020, The New England journal of medicine.

[17]  Amit N. Patel,et al.  Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[18]  S. Goodman,et al.  Clinical Trial Participants’ Views of the Risks and Benefits of Data Sharing , 2018, The New England journal of medicine.

[19]  Harlan M Krumholz,et al.  The Yale Open Data Access (YODA) Project--A Mechanism for Data Sharing. , 2016, The New England journal of medicine.

[20]  David L. DeMets,et al.  Achieving effective informed oversight by DMCs in COVID clinical trials , 2020, Journal of Clinical Epidemiology.

[21]  Philippe Ravaud,et al.  COllaborative Open Platform E-cohorts for Research Acceleration in Trials and Epidemiology (COOPERATE). , 2020, Journal of clinical epidemiology.

[22]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[23]  J. Ioannidis,et al.  Evaluation of Clinical Trial Data Sharing Policy in Leading Medical Journals , 2020, medRxiv.

[24]  Thomas Jaki,et al.  Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report , 2020, The New England journal of medicine.

[25]  G. Hripcsak,et al.  Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.

[26]  T. Editors,et al.  Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[27]  H. Krumholz,et al.  Open access to clinical trials data. , 2014, JAMA.